Simplex Castings Gets BSE Nod for ₹99.71 Crore Issue

Simplex Castings Ltd has received BSE’s in-principle approval for a preferential issue of 44,90,791 equity shares and 50,05,195 convertible warrants, with the proposed fundraising amounting to up to ₹99.71 crore at ₹105 per security. The approval advances the company’s planned capital raise after board and shareholder processes.

What did BSE approve for Simplex Castings?

BSE has granted Simplex Castings in-principle approval to issue equity shares and convertible warrants through a preferential allotment. The approval covers up to 44,90,791 equity shares and up to 50,05,195 warrants, each priced at ₹105.

The equity-share component can raise up to ₹47.15 crore, while the warrants have an aggregate value of up to ₹52.55 crore if converted into equity shares. Together, the two instruments represent a proposed fundraising of up to ₹99.71 crore. The equity shares are proposed for non-promoter category investors, while warrants are proposed for promoter and non-promoter categories.

An in-principle approval is an exchange-level regulatory step for the proposed issuance. It does not by itself mean that all warrants have been converted or that the full proposed amount has been received by the company. The warrant component is linked to conversion into equity shares under the terms of the issue.

How did the proposed fundraise progress?

The Simplex Castings board approved the capital-raising proposal at its meeting on September 23, 2026. Along with the proposed preferential issue, the board approved an increase in authorised share capital to ₹15 crore from ₹10 crore to provide capacity for the new securities.

The company called an Extra-Ordinary General Meeting, or EGM, for October 15, 2026, to seek shareholder approval for the proposed issuances. The record date for voting eligibility was October 8, 2026. The EGM was held through video conference, with 40 shareholders reported to have participated.

The resolutions placed before shareholders included the authorised capital increase, the issue of equity shares to non-promoter investors, and the issue of convertible warrants to promoter and non-promoter categories. The company also considered the appointment of Urlam Jaya Manmadha Rao as an independent director, effective from September 23, 2026.

Before the EGM, Simplex Castings issued a corrigendum to the September 23 notice. The corrigendum corrected typographical matters, updated allottee names, clarified authorised-capital wording and updated the post-issue shareholding information. The company stated that the correction did not introduce new resolutions or material changes to the financial proposal.

Why is Simplex Castings raising capital through shares and warrants?

Simplex Castings has said the proposed proceeds are intended for capital expenditure, working-capital requirements and general corporate purposes. The company has indicated that funds are to be utilised within 36 months from the date of receipt.

The structure combines immediate equity issuance with warrants that can convert into shares. For the company, this provides a route to raise capital while the timing of funds attributable to warrants depends on the applicable conversion process. For investors, both the number of shares issued and the conversion of warrants are relevant because they can change the company’s equity base.

This is not the company’s first preferential fundraising exercise. In August 2025, Simplex Castings allotted preferential shares worth about ₹10.7 crore for loan repayment. It also allotted about ₹21 crore in March 2026 for working-capital requirements related to railway bogie and power-fabrication activities.

The latest proposal is therefore part of a series of capital-raising actions by the company. Its stated use of proceeds includes supporting operations and capital requirements in the heavy-engineering business, rather than a specifically disclosed acquisition or project in the available information.

What does the approval mean for investors and operations?

The BSE approval moves the proposed transaction closer to implementation, but investors should distinguish between the equity-share allotment and the potential warrant conversion. If the proposed securities are issued and warrants are converted, the number of outstanding equity shares can increase, which is a material consideration for existing shareholders.

The proposed price of ₹105 per share or warrant is the stated transaction price for the preferential issue. The available disclosures do not provide a share-price reaction, valuation assessment or revised financial forecast connected with the approval. Accordingly, the immediate confirmed development is the exchange approval for the stated quantity and price of securities.

For operations, the fundraise is intended to support capital expenditure, working capital and general corporate purposes. Working capital is particularly relevant to manufacturing and heavy-engineering companies, where production, procurement and customer-payment cycles can require significant operating funds. However, the company has not disclosed a project-wise allocation of the proposed ₹99.71 crore in the information provided.

The larger authorised share-capital base, raised from ₹10 crore to ₹15 crore, enables the company to accommodate the proposed issue. It also forms part of the corporate approvals surrounding the capital raise, alongside the board resolution, shareholder process and BSE’s in-principle clearance.

Conclusion

Simplex Castings has obtained BSE’s in-principle approval for a preferential issue comprising 44,90,791 equity shares and 50,05,195 convertible warrants at ₹105 each. The proposal has a maximum value of ₹99.71 crore and follows the company’s decision to increase authorised share capital to ₹15 crore.

The next points to watch are the allotment and issue-related disclosures, the receipt and deployment of funds, and any conversion of the proposed warrants into equity shares. Simplex Castings has identified capital expenditure, working capital and general corporate purposes as intended uses of proceeds within 36 months of receiving the funds.